Compare Amylx Pharmaceuticals Inc (AMLX) vs Home Depot Inc (HD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Home Depot Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.34 (market cap $1.98B), while Home Depot Inc trades at $343.83 (market cap $342.31B). The key difference: Home Depot Inc is far larger — about 172.9× Amylx Pharmaceuticals Inc's market cap, and Home Depot Inc pays a 2.71% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | HD | |
|---|---|---|
Market Cap | $1.98B | $342.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $423.42 |
52-Week Low | $7.64 | $297.51 |
Enterprise Value | $1.70B | $403.87B |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Home Depot (HD) trades at $343.65, up 0.1% on the day, with mixed technical signals showing a bearish overall trend but bullish moving averages. The stock's valuation metrics include a P/E of 24.38 and P/S of 2.05, with revenue reaching $159.51 billion in 2025 and net income of $14.81 billion. Recent earnings show beats in Q4 2025 and Q1 2026 but a miss in Q3 2025, while cash flow trends indicate operational strength despite a net outflow of $2.10 billion in 2025.
The outlook remains supported by analyst consensus with a $370.59 price target and 59% buy ratings, though risks include weakening big-ticket demand and margin pressures from investments. Housing market volatility and rising mortgage rates pose headwinds, but Pro customer growth and digital initiatives offer resilience for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
